Please ensure Javascript is enabled for purposes of website accessibility

2 Obesity Drugs Near the Finish Line for Launch

By Dave Williamson - Updated Apr 7, 2017 at 12:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's a ton of anticipation surrounding the launches of obesity drugs Qsymia, by Vivus(VVUS), and, coming soon, Belviq by Arena Pharmaceuticals(ARNA). During its first week on the market, it appears that health plans are more accommodating to Qsymia than even Vivus had anticipated, with almost a third of prescriptions being picked up by insurers. It's a win that neither of the drugs are terribly expensive, as cost won't be a major deterrent.

Before Arena investors start to worry about being left behind, keep in mind that only 106 scripts were written last week for Qsymia. Getting doctors comfortable with and actively prescribing the new treatments may take some time, which is why Belviq's DEA delay is not as big a deal as it might seem. In fact, the future is looking especially bright for Arena and its innovative, ready-to-launch obesity drug, making now a perfect time to check out our premium research report on Arena Pharmaceuticals. health-care analyst and Arena expert Brian Orelli, Ph.D., walks investors through the must-know opportunities -- and potential threats -- facing the future of the company. Since key news can develop quickly, Brian will continue to deliver a year's worth of updates and guidance for all who sign up. To learn more and get started, click here now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
VIVUS, Inc. Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.